Mersana Therapeutics Stock Plunges 36% After Phase 1 Trial Data Release
Mersana’s emiltatug ledadotin (Emi-Le) shows a 23% ORR in B7-H4 high tumors, including triple-negative breast cancer, but higher doses revealed proteinuria concerns, impacting its stock price. FDA granted Fast Track designation, highlighting Emi-Le’s potential despite safety challenges.
Mersana Therapeutics Stock Plunges 36% After Phase 1 Trial Data Release Read More »